Mounjaro (Tirzepatide) Single-Dose Pens
$165.00
Mounjaro is a single-dose pen containing Tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor agonist, used to improve blood sugar control in adults with type 2 diabetes.
Available: 5mg, 7.5mg, 10mg, 12.5mg, 15mg
In Stock (95 available)
Why Choose Mounjaro?
Mounjaro is the first and only GIP and GLP-1 receptor agonist, often providing superior glycemic control and weight reduction compared to older therapies.
How to Use
Inject subcutaneously once weekly, at any time of day, with or without meals. Inject in the abdomen, thigh, or upper arm. Rotate injection sites.
Safety Information
Boxed warning for thyroid C-cell tumors. Contraindicated in patients with a personal or family history of MTC or MEN 2. Risk of pancreatitis and hypoglycemia.
Potential Side Effects
Most common side effects include nausea, diarrhea, decreased appetite, vomiting, and constipation.
Product Facts
| Generic Name | Tirzepatide |
| Brand Name | Mounjaro |
| Type of Medication | GIP and GLP-1 receptor agonist |
| FDA Approval Date | May 13, 2022 |
| Indications | To improve glycemic control in adults with Type 2 Diabetes Mellitus. |
| Dosage Forms | Subcutaneous injection (single-dose pen) |
| Administration | Once weekly |
| Special Precautions | Not for use in Type 1 Diabetes or diabetic ketoacidosis. Monitor for acute kidney injury and severe gastrointestinal disease. |
| Drug Interactions | Slows gastric emptying, affecting absorption of coadministered oral drugs. |
| Use in Specific Populations | Use during pregnancy is not recommended unless potential benefit justifies the potential risk to the fetus. |
| Prescription | Prescription required |
| Manufacturer | Eli Lilly and Company |
How to Buy
Available by prescription only. Ensure you receive proper training on injection technique before first use.